For the betterment of healthcare and fuller lives of people worldwide, we aim to become an R&D-led enterprise that continuously innovates revolutionary pharmaceuticals and healthcare solutions by leveraging cutting-edge science and technology.
VXL maintains distinct divisions for both formulation and analytical tasks within its Research and Development department. The Research and Development department is outfitted with high-quality instruments aimed at facilitating the creation of various dosage forms. We can formulate both immediate release and modified release tablets through granulation, blending, and roller compaction. Small capsule batches for controlled release products can be made with fluid-bed coated particles. For pediatric formulations, we offer suspensions and orally disintegrating tablets that are taste-masked.
The R&D center at VXL features a contemporary Formulation Development (F&D) and Analytical Development (AD) facility, both equipped with state-of-the-art instruments. A robust regulatory team is committed to providing support for R&D deliverables. The entire R&D area is covered by an Air Handling Unit (AHU) system to maintain controlled conditions. To prevent cross-contamination, different areas are equipped with distinct AHUs. For sensitive products, a facility with low relative humidity and controlled environment is in place. A designated area is allocated for High-Performance Liquid Chromatography (HPLC) and other analytical instruments within the R&D setup. R&D at VXL is a tangible expression of their commitment to quality and innovation. The company prides itself on its transparent approach and proactive involvement in adhering to international standards and guidelines during the product development journey.
We have the expertise to support you in meeting all of your formulation development needs. Our expert development team is capable of developing the ideal formulations not just for conventional dosage forms, but for specialised forms as well, including complex modified release and large molecules.
Our development team can perform a range of services, including excipient compatibility studies, pre-formulation, formulation and Quality by Design (QbD) activities, all designed to help you meet your clinical objectives. From small-scale proof-of-concept prototype batches, to manufacturing clinical trial materials, from scale-up manufacturing to registration batch manufacturing, we can help you at every stage in the process.
With an integrated drug substance, drug product and device development offering, we streamline the development process, managing complexity to minimise your time-to-market.
Whatever your needs, we are here to support you in developing the formulation that will brings out the best of your drug substance.
Our expertise lies in research and development, and it is structured to innovate, formulate, and back a diverse array of products featuring alternative drug delivery methods or enhancing the stability of crucial Active Pharmaceutical Ingredients (APIs) to streamline production or pioneer novel product concepts.
Currently, VXL is actively in the process of filing patents for multiple innovative developments underway.
In the domain of product development, we have achieved the following milestones:
These initiatives underscore our dedication to advancing pharmaceutical innovation and addressing various challenges in drug delivery and formulation.